Pricing Log in Create free account

Apimeds Pharmaceuticals US, Inc. (APUS) vs cbdMD, Inc. (YCBD)

Apimeds Pharmaceuticals US, Inc. and cbdMD, Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. and cbdMD, Inc. are of similar size ($4.4M and $4.1M). Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −14.7%) and the higher return on invested capital (−16.0% vs −29.8%). Across the 13 metrics below, cbdMD, Inc. leads on 7 and Apimeds Pharmaceuticals US, Inc. on 6.

Valuation

Metric APUS YCBD Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.55
P/S n/m 0.19 2.08
P/B 0.04 0.49 1.79
Price to free cash flow n/m n/m 16.29
EV/EBITDA n/m n/m 12.22
EV/Sales n/m 0.21 2.87
Earnings yield (1,394.72%) (80.50%) (15.94%)
Free cash flow yield (295.94%) (61.46%) 0.00%

Profitability

Metric APUS YCBD Drug Manufacturers Specialty & Generic median
Gross margin — 57.68% 53.51%
Operating margin 0.00% (13.87%) 0.00%
Net margin 0.00% (14.71%) (2.45%)
Free cash flow margin 0.00% (11.51%) 0.00%
Return on equity (100.13%) (43.01%) (0.80%)
Return on assets (84.20%) (26.73%) (1.67%)
Return on invested capital (15.96%) (29.78%) 0.00%

Growth

Metric APUS YCBD Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 10.01% 5.22%
EPS growth (last fiscal year) (205.56%) 92.39% 42.91%
Revenue growth, 5-year CAGR — (14.45%) 7.24%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric APUS YCBD Drug Manufacturers Specialty & Generic median
Debt to equity 0.08 0.00 0.04
Current ratio 0.51 2.50 2.41
Net debt to EBITDA 0.38 6.17 1.01

Dividend

Metric APUS YCBD Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.45%
Payout ratio — — 0.27

Size

Metric APUS YCBD Drug Manufacturers Specialty & Generic median
Market cap 4.12m 4.35m 315.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack